This activity is expired and is no longer available for CME credit.


Therapeutic Advances in the Management of Relapsing Forms of Multiple Sclerosis

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN, FANA; Clyde E. Markowitz, MD; Patricia Melville, MSN, NP-C, MSCN
Release Date: 3/12/2021Expiration Date: 3/11/2022
Credit Type: AAPA / CME / CNENumber of Credits: 0
Content Type: VideoProvider:
Although rapid advances in the management of patients with multiple sclerosis (MS) are poised to improve patient outcomes, clinical decision-making has become more complex. There are numerous approved and emerging disease-modifying therapies (DMTs) for patients with relapsing forms of MS. Although most patients with MS present with the relapsing form, a staggering 80% go on to develop secondary progressive MS, the course associated with progressive worsening of neurologic function. The expanded pool of DMTs has changed the clinical approach to therapy. Whereas the ability of a therapy to reduce the relapse rate or disability progression has historically driven DMT selection, the emergence of new therapeutic options combined with the longevity and variable disease course of MS necessitates consideration of additional factors, such as safety, convenience, and management of comorbidities. In this continuing educational activity, expert clinicians discuss the latest updates in therapies for MS.